<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10732743</article-id><article-id pub-id-type="pmc">2374418</article-id><article-id pub-id-type="pii">6690996</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.0996</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fokkema</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Oosterom</surname><given-names>A T</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Uges</surname><given-names>D R A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Spinelli</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Valota</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>de Vries</surname><given-names>E G E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Groen</surname><given-names>H J M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Pulmonology, Department of Pharmacy, Department of Internal Medicine, University Hospital Groningen, PO Box 30.001, Groningen, RB, 9700, The Netherlands</aff><aff id="aff2"><label>2</label>Rotterdam Cancer Institute and University Hospital, Rotterdam, The Netherlands</aff><aff id="aff3"><label>3</label>University Hospital Leuven, Belgium</aff><aff id="aff4"><label>4</label>Pharmacia &#x00026; Upjohn, Milan, Italy</aff><pub-date pub-type="ppub"><month>02</month><year>2000</year></pub-date><volume>82</volume><issue>4</issue><fpage>767</fpage><lpage>771</lpage><history><date date-type="received"><day>06</day><month>01</month><year>1999</year></date><date date-type="rev-recd"><day>02</day><month>08</month><year>1999</year></date><date date-type="accepted"><day>25</day><month>08</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The aim of this phase I study was to assess feasibility, pharmacokinetics and toxicity of methoxymorpholino doxorubicin (MMRDX or PNU-152243) administered as a 3 h intravenous infusion once every 4 weeks. Fourteen patients with intrinsically anthracycline-resistant tumours received 37 cycles of MMRDX. The first cohort of patients was treated with 1 mg m<sup>&#x02212;2</sup>of MMRDX. The next cohorts received 1.25 mg m<sup>&#x02212;2</sup>and 1.5 mg m<sup>&#x02212;2</sup>respectively. Common toxicity criteria (CTC) grade III/IV nausea and vomiting were observed in 1/18 cycles at 1.25 mg m<sup>&#x02212;2</sup>and in 2/11 cycles at 1.5 mg m<sup>&#x02212;2</sup>. Transient elevation in transaminases up to CTC grade III was observed in 2/16 cycles at 1.25 mg m<sup>&#x02212;2</sup>and 4/11 cycles at 1.5 mg m<sup>&#x02212;2</sup>. No cardiotoxicity was observed. At 1.25 mg m<sup>&#x02212;2</sup>CTC grade IV neutropenia occurred in 1/17 cycles. At 1.5 mg m<sup>&#x02212;2</sup>CTC grade III neutropenia was seen in 2/7 and grade IV in 3/7 evaluable cycles. Thrombocytopenia grade III was observed in 2/9 and grade IV in 1/9 evaluable cycles. One patient treated at 1.5 mg m<sup>&#x02212;2</sup>died with neutropenic fever. Therefore, dose-limiting toxicity was reached and 1.25 mg m<sup>&#x02212;2</sup>was considered the maximum tolerated dose for MMRDX as 3 h infusion. No tumour responses were observed. Pharmacokinetic parameters showed a rapid clearance of MMRDX from the circulation by an extensive tissue distribution. Renal excretion of the drug and its metabolite was negligible. In conclusion, prolongation of MMRDX infusion to 3 h does not improve the toxicity profile as compared with bolus administration. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>methoxymorpholino doxorubicin</kwd><kwd>pharmacokinetics</kwd><kwd>phase I study</kwd></kwd-group></article-meta></front></article>


